Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.

We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.

[Changes of regional cerebral blood flow in patients with intracerebral hemorrhage by 133xenon inhalation method].

In 32 patients with acute and subacute intracerebral hemorrhage confirmed by CT scans, the regional cerebral blood flow (rCBF) was determined by using 133Xe inhalation method. The results showed that the mean cerebral blood flow (mCBF) of the patient group was significantly lower than that of the control group (t = 9.1287, P less than 0.001), while the difference of mCBF between the hemorrhagic and non-hemorrhagic hemisphere in the patients was not significant (P less than 0.1). In the hemorrhagic hemisphere, the mCBF was negatively correlated with the volume of hematoma (r = -0.4866, P less than 0.005).8 of the patients were examined in recovery stage, the mCBF was found to be elevated obviously, but the value was still lower than that of the normal controls. The authors are of the opinion that cerebral hemorrhage may have different mechanisms from cerebral infarction with regard to the decrease of rCBF.